Interferon Type I, Recombinant - Therapeutic use
Research News and Information

Monday, November 23, 2009

Hepatitis C: The role of new interferons in the era of STAT-C.

30 Aug 2009 More than 50% of patients infected with HCV genotype 1 fail respond to standard treatment with peginterferon plus ribavirin. potent treatment strategies are urgently needed to improve outcomes for such patients. novel interferons and specifically ... Read more...

Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis.

8 Aug 2009 BACKGROUND: Interferon beta has been approved for the treatment of multiple sclerosis (MS). It is believed that immunomodulatory rather than antiviral activity of interferon beta is responsible for disease amelioration. The impact of interferon beta ... Read more...

Efficacy of consensus interferon in treatment of HbeAg-positive chronic hepatitis B: a multicentre, randomized controlled trial.

7 Jul 2009 BACKGROUND: Consensus interferon (CIFN) is a newly developed type I interferon. AIMS: This multicentre, controlled trial was conducted to determine the efficacy of CIFN and to compare it with alpha-1b-interferon (IFN-alpha1b) in the treatment of ... Read more...

Latest indexed articles for 'Interferon Type I, Recombinant - Therapeutic use'

These are the very latest articles for this heading:

• Immunotherapy for multiple sclerosis: the curious case of interferon beta. 29 Sep 2009
• Hepatitis C: The role of new interferons in the era of STAT-C. 30 Aug 2009
• Re-treating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: really safe and effective? 30 Aug 2009
• Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis. 8 Aug 2009
• Efficacy of consensus interferon in treatment of HbeAg-positive chronic hepatitis B: a multicentre, randomized controlled trial. 7 Jul 2009
• Correlated bivariate continuous and binary outcomes: issues and applications. 13 Jun 2009
• Pharmacotherapy of multiple sclerosis: the PROOF trial. 30 May 2009
• Management of patients co-infected with HBV and HCV. 30 May 2009
• Serine protease inhibitors as anti-hepatitis C virus agents. 30 May 2009
• Treatment of HBV-related cirrhosis. 30 May 2009
• Recombinant interferon-beta therapy and neuromuscular disorders. 11 May 2009
• Treatment options for patients with chronic hepatitis C not responding to initial antiviral therapy. 8 Apr 2009
• Vitiligo and multiple sclerosis in a patient treated with interferon beta-1a: a case report. 30 Mar 2009
• Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes. 15 Mar 2009
• Gorhams disease: vanishing bone syndrome. 27 Feb 2009
• Interferon beta for primary progressive multiple sclerosis. 19 Jan 2009
• Pharmacogenomics of IFN-beta in multiple sclerosis: towards a personalized medicine approach. 30 Dec 2008
• Chemoradioimmunotherapy with 5-fluorouracil, cisplatin and interferon-alpha in pancreatic and periampullary cancer: results of a feasibility study. 6 Nov 2008
• IFN-beta regulates CD73 and adenosine expression at the blood-brain barrier. 29 Sep 2008
• Pneumococcal meningitis during antiviral treatment with interferon and ribavirin in a splenectomized patient with chronic hepatitis C - do not miss vaccination before starting therapy. 20 Sep 2008

See a longer list of these articles.

Technical information about 'Interferon Type I, Recombinant'

Definition: A type I interferon with antiviral and antineoplastic activity produced by recombinant DNA technology. It can be a mixture of alpha and beta interferons.

Registry Number: 0

Descriptor UI: D015379

Alternative terms: Interferon Type I, Recombinant; Interferon Beta, Recombinant; Beta, Recombinant Interferon; Recombinant Interferon Beta; Interferon Alfa, Recombinant; Recombinant Interferon Alfa; Interferon Alpha, Recombinant; Alpha, Recombinant Interferon; Recombinant Interferon Alpha;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications; agonists;

Pharmacological Action: Antineoplastic Agents; Antiviral Agents; Angiogenesis Inhibitors;

Tree Number: D12.644.276.374.440.890.125; D12.644.276.718.500.125; D12.776.467.374.440.890.125; D12.776.467.718.500.125; D12.776.828.200; D23.529.374.440.890.125; D23.529.718.500.125;

History Note: 2000(1989)